pifithrin has been researched along with Ovarian Neoplasms in 5 studies
pifithrin: a tetrahydrobenzothiazol; inhibitor of P53 that protects mice from the side effects of cancer therapy; structure in first source
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We explored the effect of the combination of the histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in ovarian carcinoma cell lines, including the IGROV-1 cell line and two p53 mutant platinum-resistant sublines (IGROV-1/OHP and IGROV-1/Pt1)." | 7.78 | Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells. ( Benedetti, V; Cincinelli, R; Corna, E; De Cesare, M; Gatti, L; Perego, P; Zaffaroni, N; Zunino, F, 2012) |
| " We explored the effect of the combination of the histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in ovarian carcinoma cell lines, including the IGROV-1 cell line and two p53 mutant platinum-resistant sublines (IGROV-1/OHP and IGROV-1/Pt1)." | 3.78 | Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells. ( Benedetti, V; Cincinelli, R; Corna, E; De Cesare, M; Gatti, L; Perego, P; Zaffaroni, N; Zunino, F, 2012) |
| "Pifithrin-alpha did not enhance the apoptotic response after p53 down-regulation." | 1.35 | Cyclic pifithrin-alpha sensitizes wild type p53 tumor cells to antimicrotubule agent-induced apoptosis. ( Zuco, V; Zunino, F, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zuco, V | 2 |
| Zunino, F | 3 |
| Christodoulou, MS | 1 |
| Colombo, F | 1 |
| Passarella, D | 1 |
| Ieronimo, G | 1 |
| De Cesare, M | 2 |
| Gatti, L | 1 |
| Benedetti, V | 1 |
| Corna, E | 1 |
| Cincinelli, R | 1 |
| Zaffaroni, N | 1 |
| Perego, P | 1 |
| Walton, MI | 1 |
| Wilson, SC | 1 |
| Hardcastle, IR | 1 |
| Mirza, AR | 1 |
| Workman, P | 1 |
| Fraser, M | 1 |
| Chan, SL | 1 |
| Chan, SS | 1 |
| Fiscus, RR | 1 |
| Tsang, BK | 1 |
5 other studies available for pifithrin and Ovarian Neoplasms
| Article | Year |
|---|---|
Cyclic pifithrin-alpha sensitizes wild type p53 tumor cells to antimicrotubule agent-induced apoptosis.
Topics: Apoptosis; Benzothiazoles; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Fibroblasts; | 2008 |
Synthesis and biological evaluation of imidazolo[2,1-b]benzothiazole derivatives, as potential p53 inhibitors.
Topics: Animals; Antineoplastic Agents; Benzothiazoles; Cell Line, Tumor; Disease Models, Animal; Female; Ge | 2011 |
Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X | 2012 |
An evaluation of the ability of pifithrin-alpha and -beta to inhibit p53 function in two wild-type p53 human tumor cell lines.
Topics: Animals; Benzothiazoles; Cell Cycle; Cell Line, Tumor; Cells, Cultured; Colonic Neoplasms; Female; F | 2005 |
Regulation of p53 and suppression of apoptosis by the soluble guanylyl cyclase/cGMP pathway in human ovarian cancer cells.
Topics: Adenoviridae; Apoptosis; Atrial Natriuretic Factor; bcl-2-Associated X Protein; Benzothiazoles; Casp | 2006 |